1. Scrip
  2. >>Conferences
  3. >>ASCO

Merck's Keytruda Doubled PFS In Some Colorectal Cancer Patients In ASCO Late-Breaker

 
• By Jessica Merrill

Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.

Three green arrows hitting the center of a black target and 3 darts out of the objective. Business strategy or competitive advantage concept. Space for text on the left side.
Merck's Keytruda doubled PFS in some colorectal cancer patients • Source: Shutterstock

Merck & Co. Inc.'s Phase III KEYNOTE-177 trial studying its PD-1 therapy Keytruda (pembrolizumab) versus chemotherapy showed the cancer immunotherapy should be the new standard of care for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer, lead investigator Thierry André, Sorbonne Université, told a press briefing ahead of the opening of the American Society of Clinical Oncology (ASCO) virtual meeting.

KEYNOTE-177 – one of seven late-breaker abstracts featured by ASCO – is the first Phase III trial to study Keytruda as a monotherapy versus standard of care (chemotherapy plus bevacizumab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

 
• By Dexter Jie Yan

In first confirmatory randomized controlled trial of any CAR-T therapy in solid tumors, CARsgen’s Claudin 18.2-targeting satri-cel reduced risk of death or disease progression by 63% in Chinese patients with gastric/gastroesophageal junction cancer.

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

 
• By Alaric DeArment

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.

More from Conferences

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.